Discontinued — last reported Q1 '26
Capvaxive — Sales
Merck & Co. Capvaxive — Sales decreased by 74.5% to $142.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 33.6%, from $214.00M to $142.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration, strong clinical demand, or effective commercial execution, while a decrease may signal increased competition, patent expiration, or shifts in public health immunization guidelines.
Detailed definition
This metric represents the total gross revenue generated from the commercial sale of a specific pneumococcal vaccine pro...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or vaccine franchises at other large-cap pharmaceutical companies, often evaluated against total segment revenue or therapeutic area market share.
mrk_segment_capvaxive_salesHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $94.00M | $100.00M | $214.00M | $258.00M | $489.00M | $557.00M | $142.00M |
| QoQ Change | — | — | — | — | — | — | — | +6.4% | +114.0% | +20.6% | +89.5% | +13.9% | -74.5% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | +420.2% | +457.0% | -33.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s capvaxive — sales?
- Merck & Co. (MRK) reported capvaxive — sales of $142.00M in Q1 2026.
- How has Merck & Co.'s capvaxive — sales changed year-over-year?
- Merck & Co.'s capvaxive — sales decreased by 33.6% year-over-year, from $214.00M to $142.00M.
- What does capvaxive — sales mean?
- The total revenue generated from the sales of a specific vaccine product.